Donald Nicholson, a former executive at Merck & Co Inc, has joined Muna Therapeutics ApS as an independent chair of the company’s board of directors. Muna is developing therapies for neurodegenerative disorders. Dr Nicholson was previously chief executive of Nimbus Therapeutics LLC and before that, spent 25 years at Merck. He is currently chair of the boards of three other companies including NodThera Ltd, a UK biotech working on inflammasome activation inhibitors.
Muna Therapeutics announced the appointment on 13 September 2021.
Copyright 2021 Evernow Publishing Ltd.